Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)Research in context

Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study)Research in context

Summary: Background: Donafenib demonstrates superior survival benefits and safety compared to sorafenib. Hepatic arterial infusion chemotherapy (HAIC) proves effective for large unresectable hepatocellular carcinoma (uHCC) over transarterial chemoembolization. This study aims to investigate the saf...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Gao, Zhao-Long Pan, Xiao-Hui Zhao, Lu Yang, Jun-Bo Cao, Dong-Yang Li, Hai-Jing Zheng, Chen Liu, Guang-Tao Li, Xu Bao, Xiao-Meng Liu, Wei-Hao Zhang, Xiao-Lin Zhu, Bo-Han Xiao, Tian-Qiang Song, Qiang Li, Wei Lu, Wen-Ge Xing, Wei Zhang
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:EClinicalMedicine
Subjects:
Hepatocellular carcinoma
Hepatic arterial infusion chemotherapy
Conversion therapy
Surgical resection
Immune checkpoint inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S258953702500149X
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S258953702500149X

Similar Items